The Conversation (0)
- NORTH AMERICA EDITIONAustraliaNorth AmericaWorld
05 January
Top 5 Small-cap Pharma Stocks (Updated January 2026)
Today's pharmaceutical stocks are facing the challenges of government-imposed drug price caps, waning demand for COVID-19 vaccines and global stock market upheaval.However, the industry's major underlying drivers — higher rates of cancer and chronic disease — are still at play and not expected... Keep Reading...
05 January
5 Best-performing Canadian Pharma Stocks (Updated January 2026)
From established players to up-and-coming firms, Canada's pharmaceutical landscape is diverse and dynamic.Canadian drug companies are working to discover and develop major innovations amidst an increasingly competitive global landscape. Rising technologies such as artificial intelligence are... Keep Reading...
31 December 2025
Pharma Market Forecast: Top Trends for Pharma in 2026
The pharmaceutical sector is entering 2026 at a critical juncture. While recent initial public offering (IPO) performance has been stellar, with pharma firms claiming five of the top 10 IPO returns this year, the outlook next year is dominated by significant investment headwinds. Large,... Keep Reading...
17 December 2025
InMed Announces Results of 2025 Annual General and Special Meeting
InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today confirmed that, at its annual general and special meeting of shareholders... Keep Reading...
12 December 2025
InMed Provides Update on BayMedica Commercial Business
InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today released the following statement.Recently, H.R. 5371, the "Continuing... Keep Reading...
09 December 2025
Invion Advances Global Strategy With New Licencing Agreement
Invion (ASX:IVX) has taken a major step forward with a new global licencing agreement that streamlines its rights across key cancer and infectious disease programs. The move gives the company a clearer path to advance its Photosoft technology, expand market opportunities and strengthen... Keep Reading...
Interactive Chart
Latest Press Releases
Related News
TOP STOCKS
American Battery4.030.24
Aion Therapeutic0.10-0.01
Cybin Corp2.140.00